Fresh off the high of its Nas­daq IPO de­but, and the low of com­par­isons to Cymabay — whose NASH drug re­cent­ly stum­bled — Gen­fit on Mon­day un­veiled an up to $228 mil­lion deal with transpa­cif­ic biotech Terns Phar­ma­ceu­ti­cals to de­vel­op its flag­ship ex­per­i­men­tal liv­er drug — elafi­bra­nor — in Greater Chi­na.

The deal comes weeks af­ter Gen­fit $GN­FT is­sued a fiery de­fense of its dual PPAR ag­o­nist elafi­bra­nor, when com­peti­tor Cymabay’s PPARδ ag­o­nist, se­ladel­par, fiz­zled in a snap­shot of da­ta from an on­go­ing mid-stage tri­al. The main goal at the end of 12 weeks was for se­ladel­par to in­duce a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in liv­er fat con­tent, but da­ta showed that pa­tients on the place­bo ac­tu­al­ly per­formed bet­ter.

The two treat­ments be­long to a fam­i­ly of drugs that ac­ti­vate pro­teins called per­ox­i­some pro­lif­er­a­tor-ac­ti­vat­ed re­cep­tors (PPARs), which reg­u­late gene ex­pres­sion. Ex­ist­ing ev­i­dence sug­gests that in the liv­er, PPAR ag­o­nists play a role in bile acid syn­the­sis, in­flam­ma­tion, fi­bro­sis and lipid me­tab­o­lism.

NASH is an un­treat­ed fat­ty liv­er dis­ease that has rav­aged the de­vel­oped world, cre­at­ing a lu­cra­tive tar­get that has sparked a flur­ry of drug de­vel­op­ment from bio­phar­ma firms big and small. It is char­ac­ter­ized by a buildup of ex­cess fat in the liv­er that in­duces chron­ic in­flam­ma­tion and even­tu­al­ly cul­mi­nates in scar­ring that can lead to cir­rho­sis, liv­er fail­ure, can­cer and death.

Pas­cal Pri­gen LinkedIn

Dubbed the silent dis­ease, it is hard to di­ag­nose in the ear­ly stages, mak­ing it dif­fi­cult to es­ti­mate its preva­lence, but stud­ies show that it af­flicts up to 12% of the adult pop­u­la­tion in de­vel­oped coun­tries. Al­though there are no ap­proved drugs for the dis­ease, the size of the NASH mar­ket is ex­pect­ed to cross $20 bil­lion by 2025.

While oth­er ma­jor NASH con­tenders — Gilead $GILD (fail in Phase III) and In­ter­cept $ICPT (mixed win in Phase III) — have dis­closed the top-line num­bers of their late-stage tri­als, Gen­fit is ex­pect­ed to come out with its Phase III in­ter­im re­sults by the end of 2019, or ear­ly 2020.

Late-stage da­ta on In­ter­cept’s drug — obeti­cholic acid (OCA) — showed it in­duced a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in fi­bro­sis, but not NASH res­o­lu­tion, and a high­er-than-ex­pect­ed num­ber of pa­tients dropped out due to the pesky side-ef­fect of itch­ing. In con­trast to In­ter­cept, Gen­fit has em­pha­sized that elafi­bra­nor’s po­ten­tial in NASH res­o­lu­tion and re­duc­ing CV risk along with a be­nign safe­ty and tol­er­a­bil­i­ty pro­file have set it apart.

“We think we’re go­ing to be the first drug on the mar­ket that can re­solve NASH,” Gen­fit’s COO Dean Hum stressed in an in­ter­view with End­points News.

He sug­gest­ed that Cymabay had “made a mis­take” to fo­cus on liv­er fat, when they should have con­cen­trat­ed on in­flam­ma­tion and fi­bro­sis — the fac­tors that con­sti­tute NASH res­o­lu­tion.

But some an­a­lysts are not quite as con­vinced.

In the af­ter­math of the Cymabay da­ta, Baird’s Bri­an Sko­r­ney sug­gest­ed se­ladel­par and elafi­bra­nor are be­gin­ning to ap­pear more sim­i­lar than dif­fer­ent.

“Though the two med­ica­tions were thought to have dif­fer­en­ti­at­ed mech­a­nisms of ac­tion, it seems that this may not be the case, as se­ladel­par’s da­ta sug­gest that the med­ica­tion does not re­duce liv­er fat, which is sim­i­lar to what we have seen from ear­li­er tri­als of elafi­bra­nor. This leads us to be­lieve that these two PPARs look much more sim­i­lar than dif­fer­ent. Hence, CymaBay may be at a sig­nif­i­cant dis­ad­van­tage mov­ing for­ward as we be­lieve that even if PPAR ag­o­nism is suc­cess­ful in Gen­fit‘s Phase 3 tri­al, with­out any clear signs of dif­fer­en­ti­a­tion, CymaBay may have an up­hill bat­tle as they work to catch up to Gen­fit in NASH. If elafi­bra­nor fails in NASH, it would prob­a­bly be pre­dic­tive of the out­come of se­ladel­par in NASH. Ei­ther way, we think this makes the PPAR class, as a whole, look like a less sig­nif­i­cant com­pet­i­tive threat to OCA.”

While the bulk of obe­si­ty and re­lat­ed dis­eases have tra­di­tion­al­ly been the wheel­house of the West­ern world, rapid ur­ban­iza­tion in parts of Asia has nor­mal­ized seden­tary lifestyles and over­nu­tri­tion, set­ting the stage for obe­si­ty in epi­dem­ic pro­por­tions. A study pub­lished in 2017 sug­gests the in­ci­dence of obe­si­ty has been in­creas­ing at an alarm­ing rate, par­tic­u­lar­ly in Chi­na, Japan and In­dia. “The num­ber of obese Chi­nese peo­ple was be­low 0.1 mil­lion in 1975, ris­ing to 43.2 mil­lion in 2014 and ac­count­ing for 16.3% of glob­al obe­si­ty,” re­searchers found.

Gen­fit’s new part­ner Terns is well versed in NASH. Last year, it joined forces with Eli Lil­ly to de­vel­op the US drug­mak­er’s ear­ly-stage NASH as­sets, in ad­di­tion to its own.

Un­der the deal, Terns — which has op­er­a­tions in Cal­i­for­nia, as well as a set­up in Chi­na — will hand over $35 mil­lion up­front, in ad­di­tion to up to $193 mil­lion in po­ten­tial mile­stone pay­ments to de­vel­op Gen­fit’s late-stage as­set elafi­bra­nor for use in NASH and pri­ma­ry bil­iary cholan­gi­tis (PBC).

A key rea­son be­hind the deal was that since elafi­bra­nor’s ex­ist­ing late-stage study does not in­clude Chi­nese pa­tients, an­oth­er Phase III study in­clud­ing such pa­tients would be re­quired for Chi­nese ap­proval, Pas­cal Pri­gent, Gen­fit’s ex­ec­u­tive VP of mar­ket­ing and com­mer­cial de­vel­op­ment, told End­points News.

By Natasha Cowan, Content Marketing Manager at Blue Latitude Health.
Many stakeholders are confused by novel precision medicines, including patients and healthcare professionals. So, how can industry help them to navigate this complexity?

Precision medicine represents a new paradigm in healthcare. It embodies the shift from treating many patients with the same therapy, to having the tools to identify the best treatment for every patient.

The short seller Muddy Waters is taking aim at Japan’s most profitable biotech, projecting a slide for a company that has skyrocketed over the last four years. Meanwhile, the firm tweeted out an analysis accusing FibroGen of manipulating data to obscure safety concerns in their latest reveal, although some investors seem satisfied by the biotech’s explanation.

Muddy Waters shorted PeptiDream, a Japanese biotech-for-hire that leveraged its peptide library into partnerships with some of the world’s largest pharmaceutical companies, a 50% profit margin and $6 billion valuation. The firm noted that despite its esteem, PeptiDream has failed to bring a drug to market 13 years after its 2006 launch (although this is not especially rare for biotech).

Having served in Afghanistan, the navy veteran leading California-based EpicentRx wants to leave no patient behind with his arsenal of anti-cancer drugs. On Thursday, the company was given a $35 million boost to further its mission.

The injection of funds will be used to shepherd its late-stage CD47 drug, RRx-001, to the FDA for marketing, and its oncolytic virus program into the clinic.

RRx-001, engineered as an agent that makes tumor cells more sensitive to therapy, is in a Phase III trial in combination with chemotherapy for use in third-line and beyond small cell lung cancer (SCLC). The drug has been granted orphan drug designation from FDA for SCLC, neuroendocrine cancer and glioblastoma.